Exact Sciences Co. (NASDAQ:EXAS) Stake Boosted by Tower Research Capital LLC TRC

Tower Research Capital LLC TRC boosted its holdings in shares of Exact Sciences Co. (NASDAQ:EXAS - Free Report) by 1,063.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 12,849 shares of the medical research company's stock after acquiring an additional 11,745 shares during the period. Tower Research Capital LLC TRC's holdings in Exact Sciences were worth $722,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in EXAS. Tidal Investments LLC increased its stake in Exact Sciences by 172.2% during the third quarter. Tidal Investments LLC now owns 34,275 shares of the medical research company's stock worth $2,335,000 after acquiring an additional 21,683 shares during the last quarter. Synovus Financial Corp purchased a new stake in shares of Exact Sciences in the 3rd quarter valued at approximately $490,000. American Trust acquired a new position in shares of Exact Sciences in the 3rd quarter worth approximately $229,000. GAMMA Investing LLC boosted its position in shares of Exact Sciences by 29.1% during the 4th quarter. GAMMA Investing LLC now owns 3,674 shares of the medical research company's stock worth $206,000 after purchasing an additional 828 shares during the period. Finally, Modus Advisors LLC acquired a new stake in Exact Sciences in the 4th quarter valued at approximately $43,000. Hedge funds and other institutional investors own 88.82% of the company's stock.

Exact Sciences Stock Up 11.2 %

NASDAQ EXAS traded up $5.30 on Friday, reaching $52.46. The company had a trading volume of 4,037,417 shares, compared to its average volume of 2,409,814. Exact Sciences Co. has a 1 year low of $39.97 and a 1 year high of $72.83. The firm has a market capitalization of $9.74 billion, a PE ratio of -9.45 and a beta of 1.14. The company has a debt-to-equity ratio of 0.97, a current ratio of 2.15 and a quick ratio of 1.93. The firm has a 50-day moving average of $44.99 and a 200-day moving average of $53.55.

Exact Sciences (NASDAQ:EXAS - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The medical research company reported ($0.21) earnings per share for the quarter, beating analysts' consensus estimates of ($0.37) by $0.16. Exact Sciences had a negative return on equity of 5.29% and a negative net margin of 37.29%. The firm had revenue of $706.79 million during the quarter, compared to analyst estimates of $688.58 million. During the same quarter last year, the firm earned ($0.60) EPS. Exact Sciences's quarterly revenue was up 10.9% on a year-over-year basis. On average, equities research analysts anticipate that Exact Sciences Co. will post -0.58 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on EXAS shares. Mizuho assumed coverage on Exact Sciences in a research note on Thursday, April 10th. They set an "outperform" rating and a $60.00 target price on the stock. Guggenheim reissued a "buy" rating and issued a $60.00 price target on shares of Exact Sciences in a research report on Friday, April 11th. Piper Sandler cut their price objective on Exact Sciences from $75.00 to $70.00 and set an "overweight" rating on the stock in a research report on Wednesday, February 26th. Robert W. Baird boosted their price objective on Exact Sciences from $69.00 to $72.00 and gave the stock an "outperform" rating in a research report on Friday. Finally, William Blair reiterated an "outperform" rating on shares of Exact Sciences in a research note on Thursday, February 20th. Two research analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $69.80.

Exact Sciences Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.